Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
12. Juni 2023 08:59 ET
|
Neuronetics
MALVERN, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
26. Mai 2023 08:59 ET
|
Neuronetics
MALVERN, Pa., May 26, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
24. Mai 2023 16:30 ET
|
Neuronetics
MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of...
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
23. Mai 2023 08:46 ET
|
Neuronetics
MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
15. Mai 2023 08:56 ET
|
Neuronetics
MALVERN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics to Present at the JMP Securities Life Sciences Conference
09. Mai 2023 17:00 ET
|
Neuronetics
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming...
Neuronetics Reports Record First Quarter 2023 Financial and Operating Results
09. Mai 2023 07:30 ET
|
Neuronetics
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming...
Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
08. Mai 2023 08:47 ET
|
Neuronetics
MALVERN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05. Mai 2023 08:30 ET
|
Neuronetics
MALVERN, Pa., May 05, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
03. Mai 2023 08:58 ET
|
Neuronetics
MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...